| [1] |
Aamodt A, Nordsletten L, Havelin LI, et al. Documentation of hip prostheses used in Norway: a critical review of the literature from1996-2000[J]. Acta Orthop Scand, 2004, 75(6): 663-676.
|
| [2] |
Cram P, Lu X, Kaboli PJ, et al. Clinical characteristics and outcomes of medicare patients undergoing total hip arthroplasty, 1991-2008[J]. JAMA, 2011, 305(15): 1560-1567.
|
| [3] |
Cram P, Lu X, Kates SL, et al. Total knee arthroplasty volume, utilization, and outcomes among medicare beneficiaries, 1991-2010[J]. JAMA, 2012, 308(12): 1227-1236.
|
| [4] |
Peter WF, Dekker J, Tilbury C, et al. The association between comorbidities and pain, physical function and quality of Life following hip and knee arthroplasty[J]. Rheumatol Int, 2015, 35(7): 1233-1241.
|
| [5] |
Kirkness CS, Mcadam-Marx C, Unni S, et al. Characterization of patients undergoing total hip arthroplasty in a real-world setting and pain related medication prescriptions for management of postoperative pain[J]. J Pain Palliat Care Pharmacother, 2003, 27(3): 235-243.
|
| [6] |
Hustedt JW, Goltzer O, Bohl DD, et al. Calculating the cost and risk of comorbidities in total joint arthroplasty in the United States[J]. J Arthroplasty, 2017, 32(2): 355-361.e1.
|
| [7] |
Podmore B, Hutchings A, van der Meulen J, et al. Impact of comorbid conditions on outcomes of hip and knee replacement surgery: a systematic review and meta-analysis[J/OL]. BMJ Open, 2018, 8(7): e021784. DOI: 10.1136/bmjopen-2018-021784.
|
| [8] |
Sarfati D. Review of methods used to measure comorbidity in cancer populations: no Gold standard exists[J]. J Clin Epidemiol, 2012, 65(9): 924-933.
|
| [9] |
Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis[J]. Best Pract Res Clin Rheumatol, 2007, 21(5): 885-906.
|
| [10] |
Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation[J]. J Chronic Dis, 1987, 40(5): 373-383.
|
| [11] |
Katz JN, Chang LC, Sangha O, et al. Can comorbidity be measured by questionnaire rather than medical record review？[J]. Med Care, 1996, 34(1): 73-84.
|
| [12] |
Librero J, Peiró S, Ordiñana R. Chronic comorbidity and outcomes of hospital care: length of stay, mortality, and readmission at 30 and 365 days[J]. J Clin Epidemiol, 1999, 52(3): 171-179.
|
| [13] |
Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index[J]. J Clin Epidemiol, 1994, 47(11): 1245-1251.
|
| [14] |
Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data[J]. Med Care, 2005, 43(11): 1130-1139.
|
| [15] |
Lakomkin N, Goz V, Lajam CM, et al. Higher modified charlson index scores are associated with increased incidence of complications, transfusion events, and length of stay following revision hip arthroplasty[J]. J Arthroplasty, 2017, 32(4): 1121-1124.
|
| [16] |
Piuzzi NS, Strnad GJ, Esa W, et al. The main predictors of length of stay after total knee arthroplasty：patient-related or procedure-related risk factors[J]. J Bone Joint Surg Am, 2019, 101(12): 1093-1101.
|
| [17] |
Inacio M, Pratt NL, Roughead EE, et al. Evaluation of three co-morbidity measures to predict mortality in patients undergoing total joint arthroplasty[J]. Osteoarthritis Cartilage, 2016, 24(10): 1718-1726.
|
| [18] |
Li WJ, Ayers DC, Lewis CG, et al. Functional gain and pain relief after total joint replacement according to obesity status[J]. J Bone Joint Surg Am, 2017, 99(14): 1183-1189.
|
| [19] |
Etcheson JI, Gwam CU, George NE, et al. Patients with major depressive disorder experience increased perception of pain and opioid consumption following total joint arthroplasty[J]. J Arthroplasty, 2018, 33(4): 997-1002.
|
| [20] |
Elixhauser A, Steiner C, Harris DR, et al. Comorbidity measures for use with administrative data[J]. Med Care, 1998, 36(1): 8-27.
|
| [21] |
Austin SR, Wong YN, Uzzo RG, et al. Why summary comorbidity measures such as the charlson comorbidity index and elixhauser score work[J]. Med Care, 2015, 53(9): e65-e72.
|
| [22] |
Inacio MC, Pratt NL, Roughead EE, et al. Using medications for prediction of revision after total joint arthroplasty[J]. J Arthroplasty, 2015, 30(12): 2061-2070.
|
| [23] |
Sharabiani MT, Aylin P, Bottle A. Systematic review of comorbidity indices for administrative data[J]. Med Care, 2012, 50(12): 1109-1118.
|
| [24] |
Ondeck NT, Bohl DD, Bovonratwet P, et al. Discriminative ability of elixhauser's comorbidity measure is superior to other comorbidity scores for inpatient adverse outcomes after total hip arthroplasty[J]. J Arthroplasty, 2018, 33(1): 250-257.
|
| [25] |
Van Walraven C, Austin PC, Jennings A, et al. A modification of the Elixhauser comorbidity measures into a point system for hospital death using administrative data[J]. Med Care, 2009, 47(6): 626-633.
|
| [26] |
Farley JF, Harley CR, Devine JW. A comparison of comorbidity measurements to predict healthcare expenditures[J]. Am J Manag Care, 2006, 12(2): 110-119.
|
| [27] |
Groll DL, To T, Bombardier C, et al. The development of a comorbidity index with physical function as the outcome[J]. J Clin Epidemiol, 2005, 58(6): 595-602.
|
| [28] |
Groll DL, Heyland DK, Caeser M, et al. Assessment of long-term physical function in acute respiratory distress syndrome (ARDS) patients: comparison of the Charlson Comorbidity Index and the Functional Comorbidity Index[J]. Am J Phys Med Rehabil, 2006, 85(7): 574-581.
|
| [29] |
Tolk JJ, Janssen RPA, Haanstra TM, et al. Outcome expectations of total knee arthroplasty patients: the influence of demographic factors, pain, personality traits, physical and psychological status[J]. J Knee Surg, 2020, 33(10)：1034-1040.
|
| [30] |
Fishman PA, Goodman MJ, Hornbrook MC, et al. Risk adjustment using automated ambulatory pharmacy data: the RxRisk model[J]. Med Care, 2003, 41(1): 84-99.
|
| [31] |
Johnson ML, Ei SH, Tran TT, et al. Adapting the Rx-Risk-V for mortality prediction in outpatient populations[J]. Med Care, 2006, 44(8): 793-797.
|
| [32] |
Inacio MC, Pratt NL, Roughead EE, et al. Predicting infections after total joint arthroplasty using a prescription based comorbidity measure[J]. J Arthroplasty, 2015, 30(10): 1692-1698.
|
| [33] |
Cleary PD, Greenfield S, Mulley AG, et al. Variations in length of stay and outcomes for six medical and surgical conditions in Massachusetts and California[J]. JAMA, 1991, 266(1): 73-79.
|
| [34] |
Greenfield S, Apolone G, Mcneil BJ, et al. The importance of co-existent disease in the occurrence of postoperative complications and one-year recovery in patients undergoing total hip replacement. Comorbidity and outcomes after hip replacement[J]. Med Care, 1993, 31(2): 141-154.
|
| [35] |
Inacio MC, Pratt NL, Roughead EE, et al. Comparing co-morbidities in total joint arthroplasty patients using the RxRisk-V, Elixhauser, and Charlson Measures: a cross-sectional evaluation[JOL]. BMC Musculoskelet Disord, 2015, 16(1): 385. DOI: 10.1186/s12891-015-0835-4.
|
| [36] |
朱琦，徐栋梁，何沛恒，等.443例初次单侧人工髋关节置换患者术前并存疾病的临床分析[J/CD]．中华关节外科杂志(电子版)，2011，5(3)：324-328.
|